Synopsis
Synopsis
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 74381-53-6
2. Leuprorelin Acetate;h-pyr-his-trp-ser-tyr-d-leu-leu-arg-pro-nhet.ch3co2h
3. Lupron (tn)
4. Mfcd00072080
5. Fensolvi (tn)
6. Eligard (tn)
7. Lutrate (tn)
8. Leuprolide Acetate (usp)
9. Leuprorelin Acetate (jp17)
10. Schembl1651429
11. 5-oxopro-his-trp-ser-tyr-d-leu-leu-arg-pronhc2h5 Dihydrate
12. Amy12301
13. Nsc746847
14. Nsc-746847
15. Sy225936
16. Ft-0627807
17. D00989
18. Leuprorelin Acetate; Lupron; Leuprolide Acetate
Molecular Weight | 1269.4 g/mol |
---|---|
Molecular Formula | C61H88N16O14 |
Hydrogen Bond Donor Count | 16 |
Hydrogen Bond Acceptor Count | 16 |
Rotatable Bond Count | 32 |
Exact Mass | 1268.66659154 g/mol |
Monoisotopic Mass | 1268.66659154 g/mol |
Topological Polar Surface Area | 469 Ų |
Heavy Atom Count | 91 |
Formal Charge | 0 |
Complexity | 2420 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 9 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Leuprolide acetate |
Drug Label | Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin releasing hormone (GnRH or LH-RH). The analog possesses greater potency than the natural hormone. The chemical name is 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-s... |
Active Ingredient | Leuprolide acetate |
Dosage Form | Injectable |
Route | Injection |
Strength | 1mg/0.2ml |
Market Status | Prescription |
Company | Teva Pharms Usa; Sandoz; Sun Pharma Global |
2 of 2 | |
---|---|
Drug Name | Leuprolide acetate |
Drug Label | Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin releasing hormone (GnRH or LH-RH). The analog possesses greater potency than the natural hormone. The chemical name is 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-s... |
Active Ingredient | Leuprolide acetate |
Dosage Form | Injectable |
Route | Injection |
Strength | 1mg/0.2ml |
Market Status | Prescription |
Company | Teva Pharms Usa; Sandoz; Sun Pharma Global |
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-09-02
Pay. Date : 2016-04-29
DMF Number : 13822
Submission : 1998-11-06
Status : Active
Type : II
Certificate Number : R1-CEP 2001-454 - Rev 01
Issue Date : 2009-02-18
Type : Chemical
Substance Number : 1442
Status : Valid
Registration Number : 222MF10137
Registrant's Address : Hauptstrasse 144,4416 Bubendorf Switzerland
Initial Date of Registration : 2010-04-14
Latest Date of Registration :
NDC Package Code : 55463-0002
Start Marketing Date : 2001-11-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Registrant Name : Hiple Co., Ltd.
Registration Date : 2022-12-07
Registration Number : 20221207-210-J-1398
Manufacturer Name : Bachem AG
Manufacturer Address : Hauptstrasse 144, 4416 Bubendorf, Switzerland
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14440
Submission : 1999-10-08
Status : Inactive
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-06-29
Pay. Date : 2020-11-09
DMF Number : 28808
Submission : 2014-11-06
Status : Active
Type : II
Certificate Number : R1-CEP 2016-199 - Rev 00
Issue Date : 2022-08-26
Type : Chemical
Substance Number : 1442
Status : Valid
Registration Number : 224MF10165
Registrant's Address : Kloosterstraat 6, 5349 AB Oss, the Netherlands
Initial Date of Registration : 2012-08-16
Latest Date of Registration :
NDC Package Code : 60870-0425
Start Marketing Date : 1996-04-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Available Reg Filing : ASMF |
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15189
Submission : 2000-12-11
Status : Inactive
Type : II
Certificate Number : R1-CEP 2006-028 - Rev 01
Issue Date : 2015-07-15
Type : Chemical
Substance Number : 1442
Status : Withdrawn by Holder
Certificate Number : R0-CEP 2021-472 - Rev 00
Issue Date : 2022-02-28
Type : Chemical
Substance Number : 1442
Status : Valid
NDC Package Code : 60870-0425
Start Marketing Date : 1996-04-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Available Reg Filing : ASMF |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9365
Submission : 1991-09-30
Status : Active
Type : II
NDC Package Code : 11532-1450
Start Marketing Date : 1990-10-22
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (3.75mg/mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
Registrant Name : Korea Takeda Pharmaceutical Co., Ltd.
Registration Date : 2022-10-26
Registration Number : 20221026-210-J-1393
Manufacturer Name : Takeda Pharmaceutical Company Limited
Manufacturer Address : Hikari Plant: 4720, Takeda, Mitsui, Hikari, Yamaguchi 743-8502, Japan
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4476
Submission : 1982-01-25
Status : Inactive
Type : II
Certificate Number : R1-CEP 2001-441 - Rev 03
Issue Date : 2022-07-29
Type : Chemical
Substance Number : 1442
Status : Valid
NDC Package Code : 11532-1450
Start Marketing Date : 1990-10-22
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (3.75mg/mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
Registrant Name : Korea Takeda Pharmaceutical Co., Ltd.
Registration Date : 2022-10-26
Registration Number : 20221026-210-J-1393
Manufacturer Name : Takeda Pharmaceutical Company Limited
Manufacturer Address : Hikari Plant: 4720, Takeda, Mitsui, Hikari, Yamaguchi 743-8502, Japan
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6142
Submission : 1985-12-23
Status : Inactive
Type : II
NDC Package Code : 11532-1450
Start Marketing Date : 1990-10-22
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (3.75mg/mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
Registrant Name : Korea Takeda Pharmaceutical Co., Ltd.
Registration Date : 2022-10-26
Registration Number : 20221026-210-J-1393
Manufacturer Name : Takeda Pharmaceutical Company Limited
Manufacturer Address : Hikari Plant: 4720, Takeda, Mitsui, Hikari, Yamaguchi 743-8502, Japan
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
34
PharmaCompass offers a list of Leuprolide Acetate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Leuprolide Acetate manufacturer or Leuprolide Acetate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Leuprolide Acetate manufacturer or Leuprolide Acetate supplier.
PharmaCompass also assists you with knowing the Leuprolide Acetate API Price utilized in the formulation of products. Leuprolide Acetate API Price is not always fixed or binding as the Leuprolide Acetate Price is obtained through a variety of data sources. The Leuprolide Acetate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Leuprolide Acetate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Leuprolide Acetate, including repackagers and relabelers. The FDA regulates Leuprolide Acetate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Leuprolide Acetate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Leuprolide Acetate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Leuprolide Acetate supplier is an individual or a company that provides Leuprolide Acetate active pharmaceutical ingredient (API) or Leuprolide Acetate finished formulations upon request. The Leuprolide Acetate suppliers may include Leuprolide Acetate API manufacturers, exporters, distributors and traders.
click here to find a list of Leuprolide Acetate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Leuprolide Acetate DMF (Drug Master File) is a document detailing the whole manufacturing process of Leuprolide Acetate active pharmaceutical ingredient (API) in detail. Different forms of Leuprolide Acetate DMFs exist exist since differing nations have different regulations, such as Leuprolide Acetate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Leuprolide Acetate DMF submitted to regulatory agencies in the US is known as a USDMF. Leuprolide Acetate USDMF includes data on Leuprolide Acetate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Leuprolide Acetate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Leuprolide Acetate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Leuprolide Acetate Drug Master File in Japan (Leuprolide Acetate JDMF) empowers Leuprolide Acetate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Leuprolide Acetate JDMF during the approval evaluation for pharmaceutical products. At the time of Leuprolide Acetate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Leuprolide Acetate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Leuprolide Acetate Drug Master File in Korea (Leuprolide Acetate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Leuprolide Acetate. The MFDS reviews the Leuprolide Acetate KDMF as part of the drug registration process and uses the information provided in the Leuprolide Acetate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Leuprolide Acetate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Leuprolide Acetate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Leuprolide Acetate suppliers with KDMF on PharmaCompass.
A Leuprolide Acetate CEP of the European Pharmacopoeia monograph is often referred to as a Leuprolide Acetate Certificate of Suitability (COS). The purpose of a Leuprolide Acetate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Leuprolide Acetate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Leuprolide Acetate to their clients by showing that a Leuprolide Acetate CEP has been issued for it. The manufacturer submits a Leuprolide Acetate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Leuprolide Acetate CEP holder for the record. Additionally, the data presented in the Leuprolide Acetate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Leuprolide Acetate DMF.
A Leuprolide Acetate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Leuprolide Acetate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Leuprolide Acetate suppliers with CEP (COS) on PharmaCompass.
A Leuprolide Acetate written confirmation (Leuprolide Acetate WC) is an official document issued by a regulatory agency to a Leuprolide Acetate manufacturer, verifying that the manufacturing facility of a Leuprolide Acetate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Leuprolide Acetate APIs or Leuprolide Acetate finished pharmaceutical products to another nation, regulatory agencies frequently require a Leuprolide Acetate WC (written confirmation) as part of the regulatory process.
click here to find a list of Leuprolide Acetate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Leuprolide Acetate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Leuprolide Acetate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Leuprolide Acetate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Leuprolide Acetate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Leuprolide Acetate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Leuprolide Acetate suppliers with NDC on PharmaCompass.
Leuprolide Acetate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Leuprolide Acetate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Leuprolide Acetate GMP manufacturer or Leuprolide Acetate GMP API supplier for your needs.
A Leuprolide Acetate CoA (Certificate of Analysis) is a formal document that attests to Leuprolide Acetate's compliance with Leuprolide Acetate specifications and serves as a tool for batch-level quality control.
Leuprolide Acetate CoA mostly includes findings from lab analyses of a specific batch. For each Leuprolide Acetate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Leuprolide Acetate may be tested according to a variety of international standards, such as European Pharmacopoeia (Leuprolide Acetate EP), Leuprolide Acetate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Leuprolide Acetate USP).